Aequilibria Health is on a mission to prevent and fight cognitive decline, a pressing health crisis among aging population.
40% of dementia can be prevented or slowed with early intervention. Yet, there are misconceptions which often lead people to deny or underestimate early symptoms, missing timely diagnosis or preventive treatments.
Through innovative digital solutions designed to be seamlessly integrated into everyday life, we aspire to create a world where cognitive health is universally available and actively nurtured.
Dementia affects 47 million people worldwide
(approx. 5% of the world’s elderly population) and predicted to increase to 75 million in 2030. 1 new case every 3 seconds
Dementia costs were estimated at $818 billion,
equivalent to 1.1% of GGDP*. By 2030, it is estimated to rise up to $ 2 trillion.
Dementia is underdiagnosed
If a diagnosis is made, it is typically at a late stage in the disease progression.
The team
Emanuela Russo, Ph.D.
Co-founder, CEO
Emanuela is a dynamic and detail-oriented entrepreneur committed to integrating clinical evidence with technological applications to foster mental well-being. After several years in research and academia, she joined a mature neurotech company, where she optimized the company’s products while meeting key regulatory requirements and achieving clinical validation. She honed her leadership capabilities by managing cross-functional teams and conducting comprehensive market analyses to drive strategic decision-making. She has extensive experience in managing multi-point clinical trials. Additionally, she brings 15 years of expertise as a clinical psychologist and neurotherapist in the field of brain aging.
Vincenzo Varriale, Dr., Ph.D.
Co-founder, CTO
Vincenzo is keen to provide effective and affordable digital therapeutic solutions for neurocognitive disorders. He is methodical and persistent, highly skilled in coordinating projects and carrying out tasks with timeliness and creativity. Since the setup of Aequilibria in 2020, he supervised and managed the overall activities for the Company’s products. Previously, he served as CSO in a healthtech Company supporting the development of a ground-breaking wearable device. He is specialized in attention and executive functions of the brain, formerly being Adjunct Professor in Neurophysiology. He has hands-on experience in the design and deployment of digital health tools, and he is the Co-owner of several US patents.
